Post IPO with Billions of Dollars, could Anthropic and OpenAI pose a real threat to Healthcare Technology companies?

Nelson Advisors
1 hour ago
13 min read

The Paradigm Shift in Healthcare IT: Evaluating the Competitive Threat of Capitalised Foundation Model Giants

The Post-IPO Capitalisation and the Narrative Premium

The competitive landscape of the healthcare technology market is being redrawn by the massive capitalisation of foundational artificial intelligence laboratories. As both OpenAI and Anthropic advance toward historic public listings in the latter half of 2026, the financial dynamics of these entities are shifting from venture-backed speculation to public-market scale.

Anthropic has experienced an extraordinary revenue trajectory, growing from an annualised run-rate of approximately $1 billion at the end of 2024 to $9 Billion by the end of 2025, and crossing $30 Billion in annualised revenue by early 2026. This growth, representing a 1,400% year-over-year increase, has positioned Anthropic to negotiate a pre-IPO funding round of $30 Billion to $50 Billion at a valuation exceeding $900 Billion, with anchor interest from Dragoneer, General Catalyst, and Lightspeed Venture Partners. Simultaneously, OpenAI is generating $25 Billion in annualised revenue and preparing for a potential public listing at a $1 Trillion valuation, having filed its confidential S-1 on May 22nd, 2026.

This influx of capital creates an acute market asymmetry. Historically, healthcare IT vendors competed on marginal software enhancements and proprietary database access. The capital reserves of the foundational model developers allow them to absorb massive operational losses while aggressively establishing direct infrastructural footprints within major health systems.

OpenAI, for example, generated $13.1 Billion in revenue in 2025 but spent approximately $22 Billion to achieve it; the company is projected to lose $14 Billion in 2026 and does not expect conventional profitability until 2029–2030. Public markets are pricing these firms on a "Narrative Premium", the valuation gap between current cash flows and the projected consolidation of the software economy under generalist cognitive architectures. For Anthropic, this narrative is built around becoming the trusted, safety-first enterprise stack for highly regulated industries like healthcare.For OpenAI, the objective is the monopolisation of cognitive workflows through raw scale and consumer-facing ubiquity.

Metric	OpenAI	Anthropic	SpaceX
Target Public Valuation	$852 Billion – $1.0 Trillion	~$900 Billion	$1.75 Trillion – $2.0 Trillion
Capital Raise Target	~$60 Billion	~$60 Billion	$75 Billion – $80 Billion
Annualized Revenue	$25 Billion	$30 Billion	$18.7 Billion (2025)
Current Profitability	Projected $14 Billion loss (2026)	First operating profit estimated Q2 2026	Net loss ($4.28 Billion in Q1 2026)
Underwriting Banks	JPMorgan, Morgan Stanley, Goldman Sachs	Goldman Sachs, JPMorgan, Morgan Stanley	Confidential Roadshow (June 2026)
Filing Status (May 2026)	Confidential S-1 filed May 22, 2026	Pre-IPO funding round ongoing	Public S-1 filed May 20, 2026

The sheer volume of these planned capital raises, which could demand north of $200 Billion from public markets when the entire United States IPO market raised only $45 Billion in 2025, will force institutional portfolios to rebalance.Capital will inevitably rotate away from existing SaaS providers to fund these pure-play AI platforms. Equipped with these balance sheets, Anthropic and OpenAI are no longer content acting as passive infrastructure providers; they are rapidly executing vertical integration strategies directly targeting clinical, administrative, and life sciences markets.

The Reality of Direct Vertical Competition: January 2026 Launches

The structural boundaries between generalist foundation models and specialised healthcare applications dissolved in January 2026. Within a four-day window, OpenAI and Anthropic launched dedicated healthcare platforms, moving from API provision to direct clinical and consumer health market competition. OpenAI introduced ChatGPT Health for consumers on January 7th, 2026, quickly followed by OpenAI for Healthcare on January 8th, an enterprise platform powered by GPT-5 models aimed at health systems. Anthropic countered on January 11th, 2026, with Claude for Healthcare, alongside an expanded Claude for Life Sciences suite, offering a unified ecosystem that integrates consumer wellness data and enterprise clinical databases.

These platforms bypass traditional middleware by establishing native data connectors. Anthropic’s Claude for Healthcare connects directly to the Centers for Medicare & Medicaid Services (CMS) Coverage Database, the ICD-10 medical coding system, the National Provider Identifier (NPI) Registry, and PubMed’s repository of over 35 Million biomedical articles. In the life sciences vertical, Anthropic has integrated Claude with Medidata's clinical trial databases, ClinicalTrials.gov, and early drug discovery repositories like Open Targets and ChEMBL. This enables Claude to autonomously parse National and Local Coverage Determinations, draft clinical trial protocols, verify credentialing, and manage prior authorisation workflows without requiring a specialised third-party software layer.

Feature Category	OpenAI / ChatGPT for Healthcare	Anthropic / Claude for Healthcare & Life Sciences
Primary Underlying Models	GPT-5 and GPT-5.2	Claude Opus 4.5
Consumer Health Integrations	ChatGPT Health (b.well partnership; connects EHRs, Apple Health, MyFitnessPal, Weight Watchers, Peloton)	Claude Pro & Max (HealthEx, Function, Apple Health, Android Health Connect)
Administrative & Regulatory Connectors	Custom enterprise-grade APIs, Microsoft SharePoint integration	CMS Coverage Database, ICD-10 diagnosis codes, NPI Registry, PubMed
Life Sciences & Clinical Trial Connectors	Collaborative development programs (e.g., Color Health)	Medidata, ClinicalTrials.gov, bioRxiv/medRxiv, Open Targets, ChEMBL, Owkin Pathology Explorer
Early Systemic Adopters	Cedars-Sinai, HCA Healthcare, Stanford Medicine Children's, MSK, AdventHealth, Baylor Scott & White	AstraZeneca, Sanofi, Genmab, Banner Health, Flatiron Health, Veeva, Premier
Compliance Infrastructure	HIPAA-compliant business associate agreements (BAAs), customer-managed encryption keys	HIPAA-compliant BAAs; native BAAs with AWS Bedrock, Google Cloud, and Microsoft Azure

On the consumer side, these corporations are aggregating vast repositories of patient-generated health data. OpenAI's partnership with b.well allows ChatGPT Health users to link electronic health records (EHRs) from major United States providers alongside data from Apple Health, Peloton, and Weight Watchers.

This direct-to-consumer strategy leverages a massive pre-existing distribution advantage: over 230 Million people globally already ask health and wellness questions on ChatGPT weekly. At the time of ChatGPT Health's release, OpenAI reported that more than 40 million people globally used the generally available ChatGPT daily to answer health and wellness questions.

By positioning their chatbots as personal health interpreters capable of analysing medical histories, summarising lab results, and identifying fitness patterns, OpenAI and Anthropic are establishing a primary patient relationship.Consequently, traditional digital health platforms focused on patient engagement and wellness tracking face immediate commoditisation as their features are absorbed into the baseline consumer subscription models of these foundation model giants.

The API Dependency Vulnerability: The Threat of Cutoffs and Co-opetition

A significant portion of the digital health ecosystem has built its product offerings on top of commercial APIs provided by OpenAI and Anthropic. Ambient clinical documentation startups (such as Abridge, Ambience Healthcare, and EliseAI) leverage these models as core cognitive engines, wrapping them in specialised user interfaces and workflow integrations.This creates an acute strategic vulnerability characterised by platform risk and intense "co-opetition". Because these startups do not own the underlying model weights, they are structurally dependent on the pricing, uptime, and licensing terms of companies that are now actively competing in their exact vertical.

The commercial terms of service of the model providers present significant legal and operational bottlenecks. Anthropic’s terms explicitly state that customers may not access its services to build competing products, a clause that the company has actively enforced.

This is not a theoretical "what if" threat; there are clear historical precedents of these giants terminating API access to protect their market position or penalise competitors:

The April 2025 Startup Cutoff: Anthropic summarily terminated model access for a startup developer that had built a coding application on top of Claude. The termination was executed when the startup was on the verge of being acquired by Anthropic's primary rival, OpenAI, illustrating how API access can be weaponised during corporate transactions.
The August 2025 OpenAI Suspension: Anthropic suspended OpenAI’s internal developer access to Claude models.Anthropic discovered that OpenAI was connecting Claude to its internal evaluation tools to compare coding, writing, and safety performance in order to refine and test GPT-5 ahead of its public launch.
Restrictive Licensing Mandates: Google and OpenAI maintain similar restrictive policies. Google's terms explicitly warn that developers may not use its services to train models that compete with Gemini API or Google AI Studio, while OpenAI forbids users from utilising model outputs to train competing architectures.

If OpenAI or Anthropic choose to restrict API access, deprecate specific clinical endpoints, or adjust pricing models to favor their in-house solutions (such as ChatGPT for Healthcare), dependent startups have limited recourse. A termination or sudden price hike would render many middle-layer SaaS applications economically non-viable overnight.

Furthermore, as these giants build direct enterprise sales pipelines into major integrated delivery networks (such as HCA Healthcare, Cedars-Sinai, and Banner Health), they can package their foundational model services with pre-built documentation and prior authorisation tools. This directly dis-intermediates healthtech startups that charge high per-provider SaaS fees (typically $2,000 to $3,000 per clinician annually) for wrappers of the same models.

The Walled Gardens of EHR Giants: Epic and Cerner as Gatekeepers

Despite their immense capital reserves and advanced reasoning capabilities, the threat of direct displacement by OpenAI and Anthropic is mitigated by three systemic barriers: electronic health record (EHR) data gravity, clinical workflow integration costs, and the regulatory assignment of malpractice liability. These structural characteristics of the healthcare industry provide a resilient moat for specialised healthtech firms and established enterprise IT vendors.

The clinical utility of any healthcare artificial intelligence is bound to its access to real-time, structured patient data. The primary custody of this data belongs to enterprise EHR giants, notably Epic Systems and Oracle Health (Cerner), which power the vast majority of acute-care hospital beds in the United States.

These systems operate under complex, highly customised data architectures developed over decades.

While the 21st Century Cures Act mandates standardized FHIR R4 API support, actual implementation varies widely across platforms. Epic Systems, for example, maintains tight, proprietary control over its developer environment (formerly App Orchard, now the Epic App Market), utilising custom FHIR profiles and restricted sandbox environments.

Startups that have secured native, two-way integrations deep within these EHR systems, such as Suki AI’s voice-activated, two-way integration with Epic, Cerner and Meditech, possess a defensible workflow moat. A generalist model provider cannot easily replicate these deeply embedded clinical tools.

Hospital IT departments are notoriously risk-averse; adding an unbundled AI layer requires extensive API maintenance, staff training, and rigorous governance structures. The EHR vendors hold significant leverage, and they are highly likely to develop their own closed-loop, "walled-garden" AI solutions or prioritise a select group of deeply integrated, non-threatening software partners.

Platform	API Architecture Type	Sandbox Access Model	Developer Approval & Onboarding Lifecycle	Optimal Deployment Environment
Epic Systems	Controlled FHIR APIs + Proprietary Extensions	Highly restricted; strictly approval-based	MyApps portal; multi-layered vendor control; long certification cycles	Enterprise Hospital Networks (SMART on FHIR Hyperspace)
Oracle Health (Cerner)	Hybrid (FHIR + Proprietary Millennium APIs)	Open but variable across deployment sites	Code Console; faster self-service sandbox credentials	Large Health Systems with legacy HL7 v2 requirements
Athenahealth	Cloud-Native REST + FHIR APIs	High accessibility; developer-friendly	Standardized and rapid onboarding with strong developer documentation	Agile SaaS platforms and outpatient digital health apps

Epic's strategic tiering of its marketplace (the Epic Showroom) illustrates this gatekeeping mechanism. Epic categorises third-party AI integrations into the "Toolbox", a curated category following shared medical documentation standards whose members include Ambience Healthcare, Suki & Commure and "Partners and Pals," a deeper tier of integration where Abridge holds the first "Pal" status for generative AI charting.

By managing these pathways, EHR vendors can regulate which AI tools land directly in the clinician's workspace, effectively keeping generalist models at arm's length unless they partner with approved middleware.

Regulatory Frameworks, FDA Sanctions, and the Liability Barrier

The legal framework governing clinical decision support systems is a critical barrier to the entry of generalist tech companies. Under the Food and Drug Administration (FDA) statutory guidelines, any software that drives clinical decisions, such as diagnosing a condition, triaging sepsis, or recommending active treatments, is classified as a Software as Medical Device (SaMD) rather than a simple reference tool.

This classification requires formal regulatory clearance, typically through the 510(k) pathway, which demands validation studies, safety profiles, and a defined intended use. Very few generative AI systems can meet these rigorous standards without highly constrained, specialised architectures.

Crucially, both OpenAI and Anthropic have structured their commercial terms of service to explicitly disclaim all clinical liability. OpenAI's terms state that ChatGPT Health is not intended for the diagnosis or treatment of any medical condition. Anthropic similarly instructs users to seek professional clinical guidance and disclaims liability for outputs.Under current malpractice frameworks, if a clinician follows an incorrect recommendation generated by an AI and a patient is harmed, the ultimate liability remains with the clinician and the hospital system. Generalist model providers do not accept upstream professional liability.

This liability structure creates a major trust gap for health system procurement officers. An enterprise healthcare provider cannot safely deploy an autonomous system that has not undergone clinical validation and whose manufacturer disclaims all product liability.

The integration of AI into clinical workflows also introduces complex legal dynamics regarding standard of care. In malpractice litigation, mock jury studies indicate that physician liability perceptions are highly dependent on how AI is integrated. For instance, jurors are nearly 50% more likely to find a radiologist liable for missed findings if they only review a scan once after an AI flags it, compared to a workflow where they read the scan twice, once before receiving AI feedback and once after. This highlights that "the AI said so" is not a legally viable defence, and clinicians must maintain independent clinical judgment and document their explicit rationale for agreeing or disagreeing with AI-generated outputs.

Furthermore, state-level regulations are tightening. For example, California’s Assembly Bill 489 (AB489) explicitly prohibits AI systems from functioning as or pretending to be licensed healthcare practitioners, establishing strict boundaries around automated medical advice. In the administrative and payer space, automated decision-making faces severe scrutiny. The ongoing federal class-action lawsuit against UnitedHealthcare over its use of AI algorithms to automate Medicare Advantage claims denials highlights the legal risks of automating clinical determinations.

Payers and providers adopting these tools must maintain clear audit trails and human-in-the-loop validation, a requirement that clashes with the fully autonomous "agentic" visions promoted by generalist labs.

Sovereign Alternatives: Open-Source De-risking and Local Infrastructures

To mitigate the existential threats of API dependency, vendor lock-in, and competitor co-opetition, an increasing number of healthcare enterprises and digital health startups are migrating to open-source and open-weight architectures. The emergence of highly capable, medically specialised open-weight models provides a viable alternative to the proprietary cloud APIs of OpenAI and Anthropic.

Models like Llama-3-Meditron (an open-weight suite built on Llama-3.1 8B and 70B parameters) and the Me-LLaMA family have set new benchmarks for open-source clinical performance. Pre-trained on curated medical corpora—including peer-reviewed clinical guidelines, medical textbooks, and PubMed Central articles—Llama-3-Meditron-70B has demonstrated the ability to outperform proprietary systems like fine-tuned GPT-4 and MedPaLM-2 on standardised medical examinations.

Furthermore, the launch of Fully Open Meditron (MeditronFO) in 2026 introduced a completely open-source pipeline spanning clinician-audited training data, synthetic guideline-grounded question-answering generation, and automated clinical evaluation protocols.

The migration to open-source frameworks is driven by critical operational and architectural advantages:

Data Sovereignty and Enterprise Governance: Highly regulated healthcare organizations are legally constrained from sending protected health information (PHI) to third-party cloud environments. Up to 87% of Fortune 500 companies have restricted or banned generalist AI tools due to data leakage concerns. Deploying open-source models within an institution's private cloud (VPC) or on-premise hardware ensures that sensitive patient data never leaves the secure organisational perimeter.
Workflow Optimisation and Schema Compliance: Unstructured clinical notes must be mapped precisely to standardized medical ontologies (like SNOMED-CT, RxNorm, and ICD-10) to feed into downstream billing and decision-support systems. While proprietary models show strong out-of-the-box performance, specialized open-source pipelines can be deeply fine-tuned using parameter-efficient methods (PEFT/LoRA) on localized clinical datasets. This allows them to achieve equivalent schema fidelity and clinical accuracy on specific, structured tasks.
Hosting Economics at Scale: For high-volume clinical applications, such as continuous ambient transcription across thousands of daily patient visits, proprietary API costs can become prohibitive. While open-source deployments require initial capital expenditures for GPU infrastructure and technical hosting expertise, the marginal cost of running fine-tuned models on private instances is significantly lower at scale than paying perpetual token-based API fees.
Architectural Decoupling: Projects like the open-source clinical scribe platform Berta—developed and deployed at scale within Alberta Health Services (AHS) and integrated with enterprise Snowflake AI Data Cloud infrastructure—demonstrate the feasibility of sovereign clinical IT. By using a modular backend that supports local inference engines (such as vLLM or Ollama) alongside open-source transcription models (such as WhisperX), health systems are successfully establishing clinical documentation pipelines that are entirely decoupled from commercial model providers.

Strategic Recommendations for Healthtech Enterprises

The rapid capitalisation and vertical expansion of OpenAI and Anthropic represent a formidable market disruption. They are actively commoditising simple SaaS applications that function as thin software wrappers over general-purpose language APIs. To remain competitive in an environment where foundational model giants can directly build enterprise-grade clinical connectors and deploy consumer health platforms, healthcare technology vendors must structurally realign their business models.

Active Multi-Model Orchestration

Developers must transition away from single-vendor API dependencies. Applications should be architected with model-agnostic middleware layers, allowing seamless, dynamic routing between commercial endpoints (such as Claude 4.5 and GPT-5) and sovereign, open-source medical models (such as Llama-3-Meditron). This decoupling mitigates platform risks and provides immediate leverage during commercial negotiations.

Deepening the Clinical Workflow Moat

Technology providers must focus their engineering resources on the highly complex, non-commoditisable aspects of healthcare delivery. This includes securing deep, two-way SMART on FHIR integrations with dominant EHR databases, engineering highly customised, specialty-specific user interfaces, and automating complex, localised administrative workflows. The closer an application is to the core operational and financial workflows of a health system, the more insulated it is from generalist cognitive competition.

Acceptance of Regulatory and Liability Risk

Because generalist foundational model providers maintain a strict risk-avoidance posture by disclaiming clinical responsibility, specialised healthtech vendors can capture market share by positioning themselves as the medically validated, legally responsible clinical layer. By seeking formal FDA clearance for their clinical decision support systems, validating their algorithms on diverse, representative patient cohorts and explicitly assuming product liability under standard-of-care frameworks, specialised firms create a highly defensible regulatory moat that capital alone cannot easily bypass.

Ultimately, the entry of multi-billion-dollar foundational model providers into healthcare IT will not completely displace the specialised software ecosystem. Instead, it will divide the market into two distinct layers: an underlying cognitive infrastructure layer dominated by highly capitalised, general-purpose platform providers, and a highly specialised clinical workflow, integration, and regulatory validation layer owned by resilient, deeply embedded healthcare technology experts.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech